ACHIEVE-4, the Longest Phase 3 Study of Lilly’s Foundayo (orforglipron) to Date, Reaffirmed its Cardiovascular and Overall Safety Profile
Monday, April 20, 2026 – INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in...








